Patents Assigned to SALADAX BIOMEDICAL
  • Patent number: 10823739
    Abstract: The present invention provides novel peptides, compositions, and methods for creating quantitative novel compositions, as well as methods for creating quantitative standards to calibrate analytes. These peptides, compositions, and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers (e.g., Tau). Also provided are kits comprising the peptides or compositions described herein, for use in assays (e.g., sandwich immunoassays).
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: November 3, 2020
    Assignee: SALADAX BIOMEDICAL
    Inventors: Paul Rhyne, Adam J. Simon, Flora Berisha, Robert John Neely, Christopher J. Spedaliere, Claudio Mapelli
  • Patent number: 10670612
    Abstract: The present invention provides novel compositions and methods for creating quantitative standards to calibrate analytes. These compositions and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers. Also provided are kits comprising the novel compositions for use in assays, for example sandwich immunoassays.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: June 2, 2020
    Assignee: SALADAX BIOMEDICAL
    Inventors: Paul Rhyne, Claudio Mapelli, Oitak Allen Wong, Flora Berisha, Robert John Neely
  • Patent number: 9551724
    Abstract: Novel conjugates of 5-fluoro-uracil and novel 5-fluoro-uracil immunogens and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of 5-fluoro-uracil in biological fluids.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: January 24, 2017
    Assignee: SALADAX BIOMEDICAL, INC.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Dennis Stocker
  • Patent number: 8946392
    Abstract: The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: February 3, 2015
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Publication number: 20140302618
    Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
    Type: Application
    Filed: May 22, 2014
    Publication date: October 9, 2014
    Applicant: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Publication number: 20140273023
    Abstract: The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens teased out of, i.e., derived from, the 5?-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Patent number: 8771972
    Abstract: Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: July 8, 2014
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Publication number: 20140024807
    Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
    Type: Application
    Filed: March 28, 2013
    Publication date: January 23, 2014
    Applicant: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
  • Publication number: 20130245241
    Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
    Type: Application
    Filed: April 30, 2013
    Publication date: September 19, 2013
    Applicant: SALADAX BIOMEDICAL INC.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
  • Publication number: 20130211052
    Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
    Type: Application
    Filed: March 28, 2013
    Publication date: August 15, 2013
    Applicant: Saladax Biomedical Inc.
    Inventor: Saladax Biomedical Inc.
  • Patent number: 8450461
    Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: May 28, 2013
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde
  • Patent number: 8440796
    Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: May 14, 2013
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
  • Patent number: 8426143
    Abstract: The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens leased out of, i.e., derived from, the 5?-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: April 23, 2013
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Howard Sard, Christopher Spedaliere
  • Patent number: 8329416
    Abstract: Use of busulfan amide as stabilized standards in immunoassays for quantifying the amount of busulfan in samples of human biological fluids, methods for carrying out said immunoassay and kits for use in said immunoassay.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: December 11, 2012
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Yunying Li
  • Publication number: 20120302740
    Abstract: Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids.
    Type: Application
    Filed: August 8, 2012
    Publication date: November 29, 2012
    Applicant: SALADAX BIOMEDICAL INC.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline
  • Patent number: 8293492
    Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: October 23, 2012
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
  • Patent number: 8273860
    Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: September 25, 2012
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov
  • Patent number: 8263749
    Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: September 11, 2012
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov
  • Patent number: 8114621
    Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: February 14, 2012
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
  • Patent number: 8088594
    Abstract: Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: January 3, 2012
    Assignee: Saladax Biomedical Inc.
    Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Daniel J. Cline, Howard Sard, Vishnumurthy Hegde